Reading this on a mobile device? Try our optimized mobile version here:

November 12, 2012News for the transfusion medicine and cellular therapy community

  Top Story 
Quotient is on a roll with new FDA approvals & GPO contracts
More good news from Quotient! Not only do we have FDA-approved Reagent Red Blood Cells products, but also just approved Rare Antisera, including Anti-s and Anti-Wra. We also have new 3-yr agreements with Premier Inc. and the General Services Administration. Great products and value from the one manufacturer focused on manual testing. Contact us today.

  Science & Health 
  • Researchers say heart cells may work as "biological pacemaker"
    Researchers at the Technion-Israel Institute of Technology said they have created working heart muscles from patients' stem cells and skin cells. Researchers said the cells could function as a "biological pacemaker" to correct irregular or slow heartbeats. "We found that the electrical signal from the heart cells we created synchronized the beat of any surrounding heart tissue," researcher Dr. Oren Caspi said. Researchers are collaborating with heart specialists to move toward clinical trials. The Telegraph (London) (tiered subscription model) (11/11) LinkedInFacebookTwitterEmail this Story
Clinical Research: Understanding the Methodology Toolbox
Clinical Research: Understanding the Methodology Toolbox compiles articles of evidence-based research for use as an educational resource for those involved in clinical research, healthcare professionals and trainees in transfusion medicine and other medical specialties. Now in the AABB Marketplace.

  Hot Topics 

Top five news stories selected by AABB SmartBrief readers in the past week.

  • Results based on number of times each story was clicked by readers.
  Emerging Trends 
  • EHR incentives reach $8.36B for Medicare, Medicaid providers
    CMS has paid a total of $8.36 billion in EHR incentives to 165,800 doctors and hospitals through October. Medicare payments to eligible providers during October amounted to $435 million, while Medicaid incentives paid to professionals and hospitals for adopting, using and upgrading EHRs were $210 million. The most recently available data shows 22% of providers that are Medicare-eligible are meaningful users of EHRs. Healthcare IT News (11/9) LinkedInFacebookTwitterEmail this Story
  Industry News & Practice 
  • Plasma preparation device from Cytomedix wins FDA nod
    Cytomedix has obtained 510(k) clearance from the FDA to market its Angel platelet rich plasma technology, which is used to process small blood samples or mixtures of bone marrow aspirate and blood. The system is designed to allow the quick and safe preparation of concentrated plasma in clinical settings. (11/8) LinkedInFacebookTwitterEmail this Story
  • Vital raises funds to advance bio-artificial liver to Phase III trials
    A regulatory filing disclosed that Vital Therapies has gained $86.1 million since September, bringing the company's total fundraising to about $150 million. The company announced in September that the money will allow it to move its Elad bio-artificial liver to three Phase III trials in 375 patients with fulminant hepatic failure and acute alcoholic hepatitis. (11/9) LinkedInFacebookTwitterEmail this Story
  • Gilead reports promising findings for combined hepatitis C therapy
    Gilead Sciences reported at a liver disease meeting that the combination of hepatitis C drugs sofosbuvir, ribavirin and GS-5885 resulted in a 100% cure rate in patients with genotype 1 chronic hepatitis C virus. Virus infection was at undetectable levels four weeks following the combined therapy in all 25 patients involved in the trial, the company said. Reuters (11/10) LinkedInFacebookTwitterEmail this Story
  Government & Regulatory 
  Association News 
  • AABB requests nominations for 2013, 2014 Memorial Awards
    AABB is seeking nominations for its 2013 and 2014 Memorial Awards, which will honor individuals who have advanced the practice of transfusion medicine and cellular therapies. The awards are presented to recognize achievements in administration, immunohematology, quality and innovative research, and overall outstanding service. Individuals are encouraged to nominate candidates by completing and submitting the online nomination form by Jan. 25, 2013. Recipients will be honored at the 2013 AABB Annual Meeting in Denver or the 2014 AABB Annual Meeting in Philadelphia. LinkedInFacebookTwitterEmail this Story
Learn more about AABB® ->Homepage  |  Join AABB  |  Conferences  |  Marketplace

Position TitleCompany NameLocation
West Coast Account ManagerMacopharma USAUS - Nationwide
Director, LaboratorySan Diego Blood BankUS - CA - San Diego
VP Patient ServicesBlood Centers of the PacificUS - CA - San Francisco
Director, Patient Blood ManagementAABBUS - MD - Bethesda
Quality Source ConsultantBlood Systems, Inc.US - Nationwide
Quality SpecialistBlood Systems, Inc.US - NM - Albuquerque
Immunohematology Reference TechnologistLifeStreamUS - CA - San Bernardino
Help Desk SpecialistAABBUS - MD
Staff AccountantAABBUS - MD
Click here to view more job listings.

I observe the physician with the same diligence as the disease."
--John Donne,
British poet, satirist, lawyer and cleric

LinkedInFacebookTwitterEmail this Story

Subscriber Tools
Print friendly format | Web version | Search past news | Archive | Privacy policy

Corporate Relations Manager:  Tamara Zein (240) 333-6604
Job Board: AABB CareerLink
A powerful website for SmartBrief readers including:
 Recent AABB SmartBrief Issues:   Lead Editor:  Tom Parks
Managing Editor: Cristian Becker

Mailing Address:
SmartBrief, Inc.®, 555 11th ST NW, Suite 600, Washington, DC 20004
© 1999-2012 SmartBrief, Inc.® Legal Information